Since joining Optum in 1992, Valery Walker’s research has spanned numerous therapeutic areas and types of projects. She specializes in observational primary data collection studies linking administrative claims data to patient surveys and/or chart reviews.
Walker has experience in disease management programs, burden of illness studies, cross sectional and prospective observational “real world” studies, pragmatic trials, retrospective chart reviews, administrative claims and electronic health record (EHR) analysis.
Her therapeutic areas cover work in osteoporosis, schizophrenia, depression, wound management, rheumatoid arthritis, fungal infections, osteoarthritis, gout, chronic obstructive pulmonary disease, diabetic macular edema, constipation and atopic dermatitis.
Walker received her MSc from the Department of Clinical Epidemiology and Biostatistics at McMaster University, with a focus on the design, measurement and evaluation of health care research. She has published over 20 manuscripts in peer-reviewed journals.
Wittbrodt E, Millette LA, Tong J, Carlyle M, Kurlander J, Walker V, DePietro M. Patient-reported outcomes of long-acting muscarinic antagonists (LAMA) or long-acting beta2-agonists (LABA) monotherapy versus LAMA/LABA fixed dose combination (FDC) in adult patients with chronic obstructive pulmonary disease (COPD) in the real-world setting: a claims-linked survey study. Paper presented at: American Thoracic Society 2018 International Conference; 2018 May 18-23; San Diego, CA.
Wei W, Ghorayeb E, Andria ML, Walker V, Chao J, Schnitzer J, Kennedy M, Chen Z, Belland A, White J, Silverberg JI. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): Baseline treatment patterns and unmet needs assessment. Paper presented at: 76th Annual Meeting of the Society for Investigative Dermatology (SID); 2017Apr 26-29; Portland, OR.
Thorne C, Boire G, Chow A, Garces K, Liu F, Poulin-Costello M, Walker V, Haraoui B. Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study. Open Rheumatol J. 2017 Oct 24;11:123-135.
Walker V, Patel H, Kurlander JL, et al. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders. J Manag Care Spec Pharm. 2015 Sep;21(9):742a-752e.
Khanna PP, Shiozawa A, Walker V, et al. Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Prefer Adherence. 2015 Jul 9;9:971-81.
HEOR, Health Economics Outcomes Research, Health Economics, PDC, Primary Data Collection